Potentiation of anti-epileptic drugs effectiveness by pyronaridine in refractory epilepsy

Medical Hypotheses

Volumn 69, Issue 3, 2007, Pages 560-563

  Asadi Pooya, Ali Akbar ^a   Sperling, Michael R ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICONVULSIVE AGENT; CYCLOSPORIN A; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; NICARDIPINE; NIFEDIPINE; PYRONARIDINE; QUINIDINE; QUININE; TAMOXIFEN;

ABDOMINAL PAIN; ARTICLE; DIARRHEA; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SPECIFICITY; ELECTROCARDIOGRAPHY; EPILEPSY; HEART DISEASE; HEART PALPITATION; HIPPOCAMPUS; HUMAN; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SIDE EFFECT; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTICONVULSANTS; DRUG RESISTANCE; DRUG SYNERGISM; EPILEPSY; HUMANS; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NAPHTHYRIDINES; P-GLYCOPROTEIN; P-GLYCOPROTEINS; TREATMENT OUTCOME;

EID: 34447274077     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.12.054     Document Type: Article

References (21)

1. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69 (2006) 273-294
2. Ryvlin P. The modern challenges of drug resistant epilepsy. Epileptic Disord 7 Suppl. 1 (2005) S1-S2
3. Beyenburg S., Bauer J., and Reuber M. New drugs for the treatment of epilepsy: a practical approach. Postgrad Med J 80 (2004) 581-587
4. Kwan P., and Brodie M.J. Epilepsy after the first drug fails: substitution or add-on?. Seizure 9 (2000) 464-468
5. Nei M., O'Connor M., Liporace J., and Sperling M.R. Refractory generalized seizures: response to corpus collosotomy and vagal nerve stimulation. Epilepsia 47 1 (2006) 115-122
6. Schmidt D., and Loscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46 6 (2005) 858-877
7. Loscher W. Mechanisms of drug resistance. Epileptic Disord 7 Suppl. 1 (2005) S3-S9
8. Tishler D.M., Weinberg K.I., Hinton D.R., Barbaro N., Annett G.M., and Raffel C. MDR 1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36 (1995) 1-6
9. Marchi N., Hallene K.L., Kight K.M., Cucullo L., Moddel G., Bingaman W., et al. Significance of MDR 1 and multiple drug resistance in refractory human epileptic brain. BMC Med 2 (2004) 37
10. Volk H.A., Burkhardt K., Potschka H., Chen J., Becker A., and Loscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 123 (2004) 751-759
11. Sisodiya S.M., Lin W.R., Harding B.N., Squier M.V., and Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125 (2002) 22-31
12. Summers M.A., Moore J.L., and McAuley J.W. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 38 (2004) 1631-1634
13. Loscher W. How to explain multidrug resistance in epilepsy?. Epil Curr 5 3 (2005) 107-112
14. Thomas H., and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-gp. Cancer Control 8 (2003) 411-424
15. Jing Q., Chun-Zheng Y., Cai-Yun W., Shu-Bin W., Ming Y., and Jin-Hong W. Function and mechanism of pyronaridine: a new inhibitor of P-glycoprotein-mediated multidrug resistance. Acta Pharmacol Sin 23 6 (2002) 544-550
16. van Vliet E.A., van Schaik R., Edelbroek P.M., Redeker S., Aronica E., Wadman W.J., et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47 4 (2006) 672-680
17. Chang C., Lin-Hua T., and Jantanavivat C. Studies on a new antimalarial compound: pyronaridine. Trans R Soc Trop Med Hyg 86 1 (1992) 7-10
18. Chen C., and Zheng X. Development of the new antimalarial drug pyronaridine: a review. Biomed Environ Sci 5 2 (1992) 149-160
19. Looareesuwan S., Kyle D.E., Viravan C., Vanijanonta S., Wilairatana P., and Wernsdorfer W.H. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am J Trop Med Hyg 54 2 (1996) 205-209
20. Ngouesse B., Basco L.K., Ringwald P., Keundjian A., and Blackett K.N. Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg 65 6 (2001) 711-716
21. Potschka H., Baltes S., and Loscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res 58 (2004) 85-91